20-Year P. F. O. Closure Confirms Long-Term Efficacy 02/25/26
Welcome to Cardiology Today â Recorded February 25, 2026. This episode summarizes 5 key cardiology studies on topics like myocardial infarction and sudden cardiac death. Key takeaway: 20-Year P. F. O. Closure Confirms Long-Term Efficacy.
Article Links:
Article 1: Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and SCA/SCD Incidence in 104,369 Young Individuals. (Journal of the American College of Cardiology)
Article 2: Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial. (Journal of the American College of Cardiology)
Article 3: Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry. (European heart journal)
Article 4: Twenty-Year Follow-Up After Patent Foramen Ovale Closure in Patients With Paradoxical Embolism. (JAMA cardiology)
Article 5: Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial. (JAMA cardiology)
Full episode page: https://podcast.explainheart.com/podcast/20-year-p-f-o-closure-confirms-long-term-efficacy-02-25-26/
đ Featured Articles
Article 1: Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and SCA/SCD Incidence in 104,369 Young Individuals.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41738673
Summary: C. A. /S. C. D. Incidence in 104369 Young Individuals. This study documented cardiac screening outcomes for conditions associated with sudden cardiac death in 104369 young individuals between 2008 and 2018. The screening program established the diagnostic yield for cardiac conditions and identified subsequent cardiac diagnoses after initial clearance. It also quantified the incidence of sudden cardiac arrest and sudden cardiac death in this young general population after a single screening event. The study provided foundational data on population-based cardiac screening in young individuals.
Article 2: Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41493296
Summary: O. N. F. I. D. E. N. C. E. Randomized Trial. This secondary analysis of the C. O. N. F. I. D. E. N. C. E. randomized trial investigated the risk of hyperkalemia with empagliflozin, finerenone, and their combination. The analysis provided specific data on how empagliflozin, a sodium-glucose cotransporter two inhibitor, influenced hyperkalemia risk when co-administered with renin-angiotensin system inhibitors. It further clarified the hyperkalemia profile of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, both alone and in combination, informing treatment decisions for managing hyperkalemia.
Article 3: Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41736503
Summary: S. C. H. F. three registry. The European Society of Cardiology Heart Failure three registry documented in-hospital and one-year cause-specific outcomes across different heart failure phenotypes. It enrolled 10162 patients from 220 centers in 41 countries between November 2018 and December 2020. The registry found that 39 percent of patients presented with acute heart failure, with a median age of 70 years and 36 percent women, while 61 percent had outpatient heart failure. This study provides contemporary data on the outcomes and characteristics of various heart failure populations in Europe.
Article 4: Twenty-Year Follow-Up After Patent Foramen Ovale Closure in Patients With Paradoxical Embolism.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41739488
Summary: This single-center cohort study documented 20-year clinical outcomes following transcatheter patent foramen ovale closure in patients with paradoxical embolism. The long-term follow-up established the enduring safety and efficacy of this therapy for preventing recurrent ischemic events over two decades. The study provided crucial very long-term data, reinforcing patent foramen ovale closure as a definitive therapy and clarifying its extended therapeutic impact.
Article 5: Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41739450
Summary: P. E. R. I. T. I. F. Randomized Clinical Trial. The A. P. E. R. I. T. I. F. randomized clinical trial determined the effect of low-dose rivaroxaban, added to dual antiplatelet therapy, on the incidence of left ventricular thrombus. The trial found how this combination therapy influenced the risk of left ventricular thrombus formation at one month in patients after anterior S. T. segment elevation myocardial infarction. This multicenter study provided specific data on the benefit and risk profile of adding an oral anticoagulant in this patient population, impacting anticoagulation strategies.
đ Transcript
Today’s date is February 25, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Cardiac Screening for Conditions Associated With Sudden Cardiac Death: Yield, Interventions, and S. C. A. /S. C. D. Incidence in 104369 Young Individuals. This study documented cardiac screening outcomes for conditions associated with sudden cardiac death in 104369 young individuals between 2008 and 2018. The screening program established the diagnostic yield for cardiac conditions and identified subsequent cardiac diagnoses after initial clearance. It also quantified the incidence of sudden cardiac arrest and sudden cardiac death in this young general population after a single screening event. The study provided foundational data on population-based cardiac screening in young individuals.
Article number two. Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the C. O. N. F. I. D. E. N. C. E. Randomized Trial. This secondary analysis of the C. O. N. F. I. D. E. N. C. E. randomized trial investigated the risk of hyperkalemia with empagliflozin, finerenone, and their combination. The analysis provided specific data on how empagliflozin, a sodium-glucose cotransporter two inhibitor, influenced hyperkalemia risk when co-administered with renin-angiotensin system inhibitors. It further clarified the hyperkalemia profile of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, both alone and in combination, informing treatment decisions for managing hyperkalemia.
Article number three. Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the E. S. C. H. F. three registry. The European Society of Cardiology Heart Failure three registry documented in-hospital and one-year cause-specific outcomes across different heart failure phenotypes. It enrolled 10162 patients from 220 centers in 41 countries between November 2018 and December 2020. The registry found that 39 percent of patients presented with acute heart failure, with a median age of 70 years and 36 percent women, while 61 percent had outpatient heart failure. This study provides contemporary data on the outcomes and characteristics of various heart failure populations in Europe.
Article number four. Twenty-Year Follow-Up After Patent Foramen Ovale Closure in Patients With Paradoxical Embolism. This single-center cohort study documented 20-year clinical outcomes following transcatheter patent foramen ovale closure in patients with paradoxical embolism. The long-term follow-up established the enduring safety and efficacy of this therapy for preventing recurrent ischemic events over two decades. The study provided crucial very long-term data, reinforcing patent foramen ovale closure as a definitive therapy and clarifying its extended therapeutic impact.
Article number five. Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The A. P. E. R. I. T. I. F. Randomized Clinical Trial. The A. P. E. R. I. T. I. F. randomized clinical trial determined the effect of low-dose rivaroxaban, added to dual antiplatelet therapy, on the incidence of left ventricular thrombus. The trial found how this combination therapy influenced the risk of left ventricular thrombus formation at one month in patients after anterior S. T. segment elevation myocardial infarction. This multicenter study provided specific data on the benefit and risk profile of adding an oral anticoagulant in this patient population, impacting anticoagulation strategies.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
myocardial infarction, sudden cardiac death, finerenone, paradoxical embolism, dual antiplatelet therapy, cardiac screening, transcatheter closure, rivaroxaban, young population, diagnostic yield, renin-angiotensin system inhibitor, sodium-glucose cotransporter two inhibitor, registry outcomes, empagliflozin, sudden cardiac arrest, long-term outcomes, patent foramen ovale, heart failure, ejection fraction, outpatient heart failure, ischemic events, acute heart failure, S. T. segment elevation myocardial infarction, left ventricular thrombus, hyperkalemia.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow